The Favorable Kinetics and Balance of Nebivolol-stimulated Nitric Oxide and Peroxynitrite Release in Human Endothelial Cells

Overview

Journal BMC Pharmacol Toxicol

Publisher Biomed Central

Specialty Pharmacology

Date 2013 Oct 1

PMID 24074014

Citations 11

Authors

R Preston Mason

Robert F Jacob

J Jose Corbalan

Damian Szczesny

Kinga Matysiak

Tadeusz Malinski

Affiliations

Soon will be listed here.

Abstract

Background: Nebivolol is a third-generation beta-blocker used to treat hypertension. The vasodilation properties of nebivolol have been attributed to nitric oxide (NO) release. However, the kinetics and mechanism of nebivolol-stimulated bioavailable NO are not fully understood.

Methods: Using amperometric NO and peroxynitrite (ONOO⁻) nanosensors, β₃-receptor (agonist: L-755,507; antagonists: SR59230A and L-748,337), ATP efflux (the mechanosensitive ATP channel blocker, gadolinium) and P2Y-receptor (agonists: ATP and 2-MeSATP; antagonist: suramin) modulators, superoxide dismutase and a NADPH oxidase inhibitor (VAS2870), we evaluated the kinetics and balance of NO and ONOO⁻ stimulated by nebivolol in human umbilical vein endothelial cells (HUVECs). NO and ONOO⁻ were measured with nanosensors (diameter ~ 300 nm) placed 5 ± 2 μm from the cell membrane and ATP levels were determined with a bioluminescent method. The kinetics and balance of nebivolol-stimulated NO and ONOO⁻ were compared with those of ATP, 2-MeSATP, and L-755,507.

Results: Nebivolol stimulates endothelial NO release through β₃-receptor and ATP-dependent, P2Y-receptor activation with relatively slow kinetics (75 ± 5 nM/s) as compared to the kinetics of ATP (194 ± 10 nM/s), L-755,507 (108 ± 6 nM/s), and 2-MeSATP (105 ± 5 nM/s). The balance between cytoprotective NO and cytotoxic ONOO- was expressed as the ratio of [NO]/[ONOO⁻] concentrations. This ratio for nebivolol was 1.80 ± 0.10 and significantly higher than that for ATP (0.80 ± 0.08), L-755,507 (1.08 ± 0.08), and 2-MeSATP (1.09 ± 0.09). Nebivolol induced ATP release in a concentration-dependent manner.

Conclusion: The two major pathways (ATP efflux/P2Y receptors and β₃ receptors) and several steps of nebivolol-induced NO and ONOO⁻ stimulation are mainly responsible for the slow kinetics of NO release and low ONOO⁻. The net effect of this slow kinetics of NO is reflected by a favorable high ratio of [NO]/[ONOO⁻] which may explain the beneficial effects of nebivolol in the treatment of endothelial dysfunction, hypertension, heart failure, and angiogenesis.

Citing Articles

The Scavenging Effect of Myoglobin from Meat Extracts toward Peroxynitrite Studied with a Flow Injection System Based on Electrochemical Reduction over a Screen-Printed Carbon Electrode Modified with Cobalt Phthalocyanine: Quantification and Kinetics.

Hosu I, Constantinescu-Aruxandei D, Oancea F, Doni M Biosensors (Basel). 2021; 11(7).

PMID: 34356690 PMC: 8301918. DOI: 10.3390/bios11070220.

Carvedilol induces biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility.

Wang Q, Wang Y, West T, Liu Y, Reddy G, Barbagallo F Cardiovasc Res. 2020; 117(10):2237-2251.

PMID: 32956449 PMC: 8502477. DOI: 10.1093/cvr/cvaa266.

Tyrosine Kinase Inhibitor-Induced Hypertension.

Agarwal M, Thareja N, Benjamin M, Akhondi A, Mitchell G Curr Oncol Rep. 2018; 20(8):65.

PMID: 29931399 DOI: 10.1007/s11912-018-0708-8.

Nanomedical studies of the restoration of nitric oxide/peroxynitrite balance in dysfunctional endothelium by 1,25-dihydroxy vitamin D - clinical implications for cardiovascular diseases.

Khan A, Dawoud H, Malinski T Int J Nanomedicine. 2018; 13:455-466.

PMID: 29416330 PMC: 5788997. DOI: 10.2147/IJN.S152822.

Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE study.

Duprez D, Florea N, Duval S, Koukol C, Cohn J J Hum Hypertens. 2017; 32(1):20-25.

PMID: 29184167 DOI: 10.1038/s41371-017-0019-9.

References

Cockcroft J . Exploring vascular benefits of endothelium-derived nitric oxide. Am J Hypertens. 2005; 18(12 Pt 2):177S-183S. DOI: 10.1016/j.amjhyper.2005.09.001. View

Bowman A, Chen C, Ford G . Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol. 1994; 38(3):199-204. PMC: 1364790. DOI: 10.1111/j.1365-2125.1994.tb04342.x. View

Rozec B, Erfanian M, Laurent K, Trochu J, Gauthier C . Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol. 2009; 53(17):1532-8. DOI: 10.1016/j.jacc.2008.11.057. View

Georgescu A, Pluteanu F, Flonta M, Badila E, Dorobantu M, Popov D . The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol. 2005; 508(1-3):159-66. DOI: 10.1016/j.ejphar.2004.11.043. View

Mason R, Jacob R, Kubant R, Ciszewski A, Corbalan J, Malinski T . Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol. 2012; 60(5):467-73. DOI: 10.1097/FJC.0b013e31826be204. View

Ignarro L . Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl. 2004; 1:2-16. View

Ignarro L, Buga G, Wood K, Byrns R, Chaudhuri G . Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987; 84(24):9265-9. PMC: 299734. DOI: 10.1073/pnas.84.24.9265. View

Mizuno Y, Jacob R, Mason R . Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. Am J Hypertens. 2008; 21(10):1076-85. DOI: 10.1038/ajh.2008.258. View

Sorrentino S, Doerries C, Manes C, Speer T, Dessy C, Lobysheva I . Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional β1-blockade. J Am Coll Cardiol. 2011; 57(5):601-11. DOI: 10.1016/j.jacc.2010.09.037. View

10.

Mizuno Y, Jacob R, Mason R . Advances in pharmacologic modulation of nitric oxide in hypertension. Curr Cardiol Rep. 2010; 12(6):472-80. DOI: 10.1007/s11886-010-0142-5. View

11.

Mathie R, Ralevic V, Alexander B, Burnstock G . Nitric oxide is the mediator of ATP-induced dilatation of the rabbit hepatic arterial vascular bed. Br J Pharmacol. 1991; 103(2):1602-6. PMC: 1908371. DOI: 10.1111/j.1476-5381.1991.tb09834.x. View

12.

Kalinowski L, Dobrucki L, Brovkovych V, Malinski T . Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation. 2002; 105(8):933-8. DOI: 10.1161/hc0802.104283. View

13.

Janssen P, Zeitz O, Hasenfuss G . Transient and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function: protective effects of nebivolol. Eur J Pharmacol. 1999; 366(2-3):223-32. DOI: 10.1016/s0014-2999(98)00907-8. View

14.

Malinski T, Taha Z . Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature. 1992; 358(6388):676-8. DOI: 10.1038/358676a0. View

15.

Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva I, Frerart F . Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005; 112(8):1198-205. DOI: 10.1161/CIRCULATIONAHA.104.532960. View

16.

Mason R, Kubant R, Jacob R, Walter M, Boychuk B, Malinski T . Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. J Cardiovasc Pharmacol. 2006; 48(1):862-9. DOI: 10.1097/01.fjc.0000238593.67191.e2. View

17.

Mason R, Kalinowski L, Jacob R, Jacoby A, Malinski T . Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005; 112(24):3795-801. DOI: 10.1161/CIRCULATIONAHA.105.556233. View

18.

Flather M, Shibata M, Coats A, Van Veldhuisen D, Parkhomenko A, Borbola J . Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26(3):215-25. DOI: 10.1093/eurheartj/ehi115. View

19.

Jankowski M, Szczepanska-Konkel M, Kalinowski L, Angielski S . Cyclic GMP-dependent relaxation of isolated rat renal glomeruli induced by extracellular ATP. J Physiol. 2001; 530(Pt 1):123-30. PMC: 2278384. DOI: 10.1111/j.1469-7793.2001.0123m.x. View

20.

Rees D, Palmer R, Moncada S . Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1989; 86(9):3375-8. PMC: 287135. DOI: 10.1073/pnas.86.9.3375. View